CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Results of operations
- 4 Planned sale Director sold 3,080 shares at $27.07 ($83,376)
- 4 Planned sale President and CEO sold 40,000 shares at $27.69 ($1,107,600)
- SC 13G/A Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
- 4 Planned sale Director sold 30,000 shares at $29.03 ($870,900)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 3,080 shares at an average $25.00 ($77,007)
- 4 Open-market sale President and CEO sold 2,260 shares at $23.79 ($53,765)
- 4 Open-market sale Director sold 1,727 shares at $23.79 ($41,085)
- 4 Planned sale COFO and Secretary sold 8,353 shares at an average $23.99 ($200,401)
- 4 Planned sale Chief Medical Officer sold 22,458 shares at an average $24.49 ($549,928)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 8 of 40 · 789 filings